AVnovum is developing a new class of antimicrobial therapy, AVpeptides, that maintain healthy fungal microbiomes by preventing virulence and infection. AVpeptides work through mechanisms that specifically target virulent but not health-promoting microbes. AVnovum is driven by a diverse team of research scientists and advisors with scientific, entrepreneurial, and business backgrounds, who are dedicated to improving patient outcomes in those with diabetes, immunodeficiencies, and immunosuppression. AVNovum Therapeutics, Inc. is a State of Delaware registered C-corporation.